JAK3 and combined immunodeficiency syndrome: Deficiency of Jak3 results in defined clinical disorders, particularly, inactivating Jak3 mutations leads to severe combined immunodeficiency syndrome and has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.